Literature DB >> 19521796

Sarcomatoid carcinoma of the urinary bladder: a case report with immunohistochemical and molecular genetic analysis.

Tadashi Terada1.   

Abstract

The author reports a rare case of sarcomatoid carcinoma with an emphasis on immunohistochemical features. A 79-year-old man was admitted to our hospital because of hematuria. An endoscopy revealed a large polypoid tumor in the bladder, and urine cytology demonstrated malignant cells. A cystectomy was performed. The patient is now alive without metastasis 4 months after the operation. Grossly, a large polypoid tumor (5 x 6 x 5 cm) was present in the bladder. Microscopically, the tumor consisted of high-grade transitional cell carcinoma element (10% in area) and sarcomatoid element (90% in area). There was a gradual transition between the two. The tumor cells were invaded into peribladder tissue (pT3b). Immunohistochemically, the sarcomatoid element was positive for four types of pancytokeratins, high-molecular weight cytokeratin (CK), CK5/6, CK7, CK18, CK19, epithelial membrane antigen (EMA), vimentin, p53 protein, p63, Ki-67 (labeling = 92%), neuron-specific enolase (NSE), and platelet-derived growth factor receptor-alpha (PDGFRA). It was negative for CK14, CK20, melanosome, carcinoembryonic antigen (CEA), desmin, S100 protein, myoglobin, alpha-smooth muscle antigen (ASMA), CD34, chromogranin, synaptophysin, CD56, CD68, and KIT. The transitional cell carcinoma element showed similar immunoreactivity except for negative CK5/6, positive CK20, and negative vimentin. A molecular genetic analysis of KIT gene (exons 9, 11, 13, and 17) and PDGFRA (exons 12 and 18) gene with the use of PCR-direct sequencing showed no mutations. The present case is the first report of sarcomatoid carcinoma of the urinary bladder demonstrating extensive immunohistochemistry and mutational status of KIT and PDGFRA genes. The sarcomatoid carcinoma in the present case may be derived from sarcomatous differentiation of high-grade transitional cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521796     DOI: 10.1007/s12032-009-9247-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  26 in total

1.  Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth.

Authors:  Tadashi Terada; Masaharu Kawaguchi; Kazuo Furukawa; Yasutomo Sekido; Yoshiyuki Osamura
Journal:  Pathol Int       Date:  2002-11       Impact factor: 2.534

2.  Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.

Authors:  Eva Compérat; Philippe Camparo; Rachel Haus; Emmanuel Chartier-Kastler; Stephane Bart; Annick Delcourt; Alain Houlgatte; Richard François; Fréderique Capron; Annick Vieillefond
Journal:  Virchows Arch       Date:  2005-11-08       Impact factor: 4.064

Review 3.  Sarcomatoid carcinoma of the urinary bladder. A clinicopathologic analysis of 12 cases and review of the literature.

Authors:  R H Young; M R Wick; S E Mills
Journal:  Am J Clin Pathol       Date:  1988-12       Impact factor: 2.493

4.  Primary, pure, large-cell neuroendocrine carcinoma of the urinary bladder.

Authors:  S Hailemariam; A Gaspert; P Komminoth; P Tamboli; M Amin
Journal:  Mod Pathol       Date:  1998-10       Impact factor: 7.842

5.  Gastrointestinal stromal tumor of the uterus: a case report with genetic analyses of c-kit and PDGFRA genes.

Authors:  Tadashi Terada
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

6.  Large endocervical polyp with cartilaginous and osseous metaplasia: a hitherto unreported entity.

Authors:  Tadashi Terada
Journal:  Int J Gynecol Pathol       Date:  2009-01       Impact factor: 2.762

7.  Primary multiple extragastrointestinal stromal tumors of the omentum with different mutations of c-kit gene.

Authors:  Tadashi Terada
Journal:  World J Gastroenterol       Date:  2008-12-21       Impact factor: 5.742

8.  Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings.

Authors:  R Torenbeek; C E Blomjous; P C de Bruin; D W Newling; C J Meijer
Journal:  Am J Surg Pathol       Date:  1994-03       Impact factor: 6.394

9.  p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung.

Authors:  Maoxin Wu; Beverly Wang; Joan Gil; Edmond Sabo; Lorraine Miller; Li Gan; David E Burstein
Journal:  Am J Clin Pathol       Date:  2003-05       Impact factor: 2.493

10.  Transitional cell carcinoma of the urinary bladder with pseudosarcomatous stroma.

Authors:  R H Young; M R Wick
Journal:  Am J Clin Pathol       Date:  1988-08       Impact factor: 2.493

View more
  6 in total

1.  Solitary skin metastasis from sarcomatoid carcinoma of the bladder: a case report.

Authors:  Antonio Manzelli; Silvia Quaresima; Piero Rossi; Athanasios Petrou; Edoardo Ricciardi; Nicholas Brennan; Michael Kontos; Giuseppe Petrella
Journal:  J Med Case Rep       Date:  2011-09-28

2.  Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

3.  Pseudomyxoma cutis; a new entity.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

4.  Cutaneous pseudolymphoma: a case report with an immunohistochemical study.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

5.  Adenoid cystic carcinoma of the oral cavity: immunohistochemical study of four cases.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

6.  Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion.

Authors:  Nakho Chang; Hye Won Lee; Joung Eun Lim; Da Eun Jeong; Hye Jin Song; Sudong Kim; Do-Hyun Nam; Hyun Hwan Sung; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han-Yong Choi; Hwang Gyun Jeon
Journal:  Oncotarget       Date:  2016-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.